Title:
USE OF 2,3 ALKYLCARBONYLOXYBENZOIC ACIDS IN THE TREATMENT OF ANTHRAX
Document Type and Number:
WIPO Patent Application WO2004032825
Kind Code:
A3
Abstract:
A method for treating inhalation anthrax is disclosed. The inventive method comprises the use of 2,3-alkylcarbonyloxybenzoic acid and salts thereof in the prevention and treatment of lung damage caused by Bacillus anthracis and toxins produced by the bacterium. The 2,3-alkylcarbonyloxybenzoic acid may be used alone or in combination with other therapeutic agents such as antibiotics.
Inventors:
STEC KAREN J
Application Number:
PCT/US2002/035056
Publication Date:
December 02, 2004
Filing Date:
October 31, 2002
Export Citation:
Assignee:
ADVANCED LIFE SCIENCES INC (US)
International Classes:
A61K9/00; A61K31/225; A61K31/496; A61K31/545; A61K31/65; A61K31/704; A61K38/48; (IPC1-7): A61K31/60
Foreign References:
| US5143718A | 1992-09-01 | |||
| US6017906A | 2000-01-25 |
Other References:
FRITZ ET AL: "Pathology of experimental inhalation anthrax in the rhesus monkey", LABORATORY INVESTIGATION, vol. 73, no. 5, 1995, pages 691 - 702, XP002903946
DATABASE BIOSIS [online] September 2001 (2001-09-01), LAROSA ET AL: "Drotrecogin alfa (activated) reduces mortality in patients with severe sepsis irrespective of bacterial pathogen classification", XP002903235, Database accession no. PREV200200499531
DATABASE BIOSIS [online] September 2001 (2001-09-01), LAROSA ET AL: "Drotrecogin alfa (activated) reduces mortality in patients with severe sepsis irrespective of bacterial pathogen classification", XP002903235, Database accession no. PREV200200499531
Download PDF: